Abstract Number: 0069 • ACR Convergence 2021
First and Recurrent Thrombosis Risk After 3842 Patient-Years of Follow-Up: Prospective Results from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (
Background/Purpose: APS ACTION “Registry” was created to study the natural course of disease over 10 years in persistently antiphospholipid antibody (aPL)-positive patients with/without other systemic…Abstract Number: 0074 • ACR Convergence 2021
Association of Anti-phospholipid Antibodies (aPL) with Poor Clinical Outcomes in Hospitalized Patients with COVID-19
Background/Purpose: Critically ill patients with COVID-19 infection have a profound hypercoagulable state and can often develop thromboses in many different vascular beds. Given the presence…Abstract Number: 012 • 2020 Pediatric Rheumatology Symposium
Pediatric Antiphospholipid Syndrome: Clinical Features and Therapeutic Interventions in a Series of 22 Cases
Background/Purpose: Pediatric antiphospholipid syndrome (APS) is a thromboinflammatory disease classically defined by the presence of circulating antiphospholipid antibodies and either thrombotic events or pregnancy morbidity.…Abstract Number: 129 • 2019 ACR/ARP Annual Meeting
Surface Proteins on Exosomes Derived from Plasma of APS Patients Indicate an Altered Immune, Cell Adhesion and Coagulation Profile
Background/Purpose: Antiphospholipid syndrome (APS) is characterized by thromboses and/or obstetric complications in presence of antiphospholipid antibodies (aPL). Extracellular vesicles have been suggested to play a…Abstract Number: 133 • 2019 ACR/ARP Annual Meeting
Anti-β2GPI Domain 1 Antibodies Stratify High Risk of Thrombosis and Pregnancy Morbidity in a Large Cohort of Chinese Patients with Antiphospholipid Syndrome
Background/Purpose: Anti-β2GPI-Domain 1 (β2GPI -D1) antibodies are currently considered to be a pathogenic subset of anti-β2GPI antibodies and have been strongly associated with thrombosis and…Abstract Number: 196 • 2019 ACR/ARP Annual Meeting
Risk of Subsequent Atherosclerotic Cardiovascular Disease After the First Unprovoked Venous Thromboembolism in Patients with Rheumatoid Arthritis
Background/Purpose: With the advent of JAK inhibitors has come increased concerns for the risk of venous thromboembolism (VTE), which was already known to be increased…Abstract Number: 204 • 2019 ACR/ARP Annual Meeting
Real-World Evidence: Clinical and Economic Burden of Anemia, Venous Thromboembolism, and Malignancy Among Rheumatoid Arthritis Patients Switching from First Biologic DMARD to Another Treatment in the US
Background/Purpose: RA patients have an increased risk of malignancy1 and deep-vein thrombosis and pulmonary embolism (DVT/PE)2 and high prevalence of anemia.3 The risks of anemia…Abstract Number: 637 • 2019 ACR/ARP Annual Meeting
How Often Should SLE Patients Be Tested for Lupus Anticoagulant?
Background/Purpose: SLE patients with persistent lupus anticoagulant (LAC) have been observed to be at significantly higher risk of thrombosis. A common clinical definition of persistent…Abstract Number: 923 • 2019 ACR/ARP Annual Meeting
First Cardiovascular Event in Rheumatoid Arthritis: Do Patients with Venous Thromboembolism Have a Different Risk Profile Than Patients with Atherosclerotic Cardiovascular Disease?
Background/Purpose: Chronic inflammation is linked to increased risk of cardiovascular disease (CVD) in RA that may manifest as venous thromboembolism (VTE) or atherosclerotic CVD (ASCVD).…Abstract Number: 1602 • 2019 ACR/ARP Annual Meeting
Persistency in Platelet C4d and Thrombosis Risk Score Associate with Thrombosis in Systemic Lupus Erythematosus
Background/Purpose: A thrombosis risk score containing abnormal Platelet-bound C4d (PC4d), low complement C3 and abnormal anti-phosphatidyl serine prothrombin (PS/PT) IgG antibody has been shown to…Abstract Number: 1825 • 2019 ACR/ARP Annual Meeting
Comparison of the Thrombosis Risk Score with Triple Positivity in SLE Thrombosis
Background/Purpose: We previously developed a Thrombosis Risk Score, a sum of three factors: lupus anticoagulant (by RVVT confirm); low C3; and C4d bound to platelets.…Abstract Number: 2964 • 2016 ACR/ARHP Annual Meeting
Thromboangiitis Obliterans (Buerger’s disease) : An Observational Study of 174 Patients
Background/Purpose: Buerger’s disease or thromboangiitis obliterans (TAO) is a nonatherosclerotic segmental inflammatory disease of small- and medium-sized arteries of the distal extremities. This disease mainly…Abstract Number: 1404 • 2012 ACR/ARHP Annual Meeting
There Is an Association Between Disease Activity and Risk of Thromboembolism in SLE
Background/Purpose: Venous thromboembolism is a recognized complication of systemic lupus erythematosus (SLE). The role of antiphospholipid antibodies (aPL) in thrombogenesis is well documented; much less…Abstract Number: 650 • 2012 ACR/ARHP Annual Meeting
Clinical Variables Associated with Thrombosis At Systemic Lupus Erythematosus Diagnosis. Differences Between Patients with Positive/Negative Lupus Anticoagulant
Background/Purpose: Thrombosis in patients with Systemic Lupus Erythematosus (SLE) is a major cause of morbidity, it occurs in 9-37%, at younger age, and it represents…